Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Nov 26;8:17369. doi: 10.1038/s41598-018-35030-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2018

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Time course of the survival rates of mice treated with bvPLA2 followed by Aβ immunization with or without PT. To induce a model of neuro-inflammation in C57BL/6 mice, the antigen suspension was mixed with 1:1 with CFA, and 100 µg of the Aβ1-42 peptide was injected subcutaneously. 500 ng of PT was intravenously administered the same day and 48 h later Aβ immunization. 0.5 mg/kg of bvPLA2 was given to mice after Aβ immunization. Mice were monitored for survival over 60 days. The survival rate was evaluated using Kaplan-Meier curves. **P < 0.01 and ***P < 0.01 vs. Aβ + PT + bvPLA2.